These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8765436)

  • 41. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.
    Wilson SC; Howard PW; Forrow SM; Hartley JA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
    J Med Chem; 1999 Oct; 42(20):4028-41. PubMed ID: 10514273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.
    Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; Van Zeist AJ; Van Den Broek LA; Ottenheijm HC
    Anticancer Res; 1992; 12(1):167-70. PubMed ID: 1567164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
    Wade Calcutt M; Lee W; Puzanov I; Rothenberg ML; Hachey DL
    J Mass Spectrom; 2008 Jan; 43(1):42-52. PubMed ID: 17683023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents.
    Gondal JA; Preuss HG; Swartz R; Rahman A
    Eur J Cancer; 1993; 29A(11):1536-42. PubMed ID: 8217358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical pharmacology of 1069C85, a novel tubulin binder.
    Raynaud FI; Kelland LR; Walton MI; Judson IR
    Cancer Chemother Pharmacol; 1994; 35(2):169-73. PubMed ID: 7987996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
    Gregson SJ; Howard PW; Hartley JA; Brooks NA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
    J Med Chem; 2001 Mar; 44(5):737-48. PubMed ID: 11262084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity and DNA binding of new organoamidoplatinum (II) complexes.
    Talarico T; Phillips DR; Deacon GB; Rainone S; Webster LK
    Invest New Drugs; 1999; 17(1):1-15. PubMed ID: 10555118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
    Goddard PM; Valenti MR; Harrap KR
    Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
    Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
    Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.
    Goddard PM; Jones M; Pollard LA; Valenti MR; Harrap KR
    Cancer Chemother Pharmacol; 1990; 25(5):377-9. PubMed ID: 2155065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo antitumor activity of benzyl isothiocyanate: a natural product from Tropaeolum majus.
    Pintão AM; Pais MS; Coley H; Kelland LR; Judson IR
    Planta Med; 1995 Jun; 61(3):233-6. PubMed ID: 7617765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M; Workman P
    Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
    Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
    Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies of the mode of action of antitumour triazenes and triazines-V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism.
    Ross D; Langdon SP; Gescher A; Stevens MF
    Biochem Pharmacol; 1984 Apr; 33(7):1131-6. PubMed ID: 6424683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes.
    McKeage MJ; Berners-Price SJ; Galettis P; Bowen RJ; Brouwer W; Ding L; Zhuang L; Baguley BC
    Cancer Chemother Pharmacol; 2000; 46(5):343-50. PubMed ID: 11127937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The metabolism and antitumour activity of the enantiomers of cis- and trans-4-methylcyclophosphamide.
    Farmer PB; Jarman M; Facchinetti T; Pankiewicz K; Stec WJ
    Chem Biol Interact; 1977 Jul; 18(1):47-57. PubMed ID: 890840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose.
    Evans SM; Young D; Robertson IG; Paxton JW
    Cancer Chemother Pharmacol; 1992; 31(1):32-6. PubMed ID: 1458557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.
    Chabot GG; Bissery MC; Corbett TH; Rutkowski K; Baker LH
    Cancer Chemother Pharmacol; 1989; 24(1):15-22. PubMed ID: 2597279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects in bacterial systems of Pt(II) complexes with antitumour activity.
    Tamaro M; Venturini S; Monti-Bragadin C; Saincich G; Mestroni G; Zassinovich G
    Chem Biol Interact; 1979 Jul; 26(2):179-84. PubMed ID: 378446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.